3rd European Lung Cancer Congress (ELCC), Geneva, Switzerland:
"Delivery of pathology for personalised treatment of lung cancer: Immunohistochemistry"
12th International lung Cancer Congress, Carlsbad, CA. USA:
Invited speaker: “Biomarkers for Personalized lung Cancer therapy.
Washington DC: Oncology Seminar arranged by Medimmune, Gaithersburg, MD:
Invited Speaker: “IGFR in Lung Cancer Therapy and Potential Predictive Markers”.
Washington Cancer Institute, Washington Hospital Center DC: “Maintenance Therapy in Lung Cancer” Educational Program (CME, IMER, Johns Hopkins University),
Tel Aviv, Israel: Israel Lung Cancer Society: Inaugural Annual Meeting:
Invited Key- Note Speaker: “ Development of Targeted Therapies in Lung Cancer”.
Roswell Park Cancer Center:
Grand Round Lecture:" Biomarker Development for Targeted Therapy in Lung Cancer".
AZ: TUCSON- Symposium:
Invited Speaker and Chairman: “Personalized Medicine in lung Cancer". (Symposium arranged by Ventana-Roche).
London, UK: EGFR Summit (Key-Opinion Leader Consensus Conference):
Invited Speaker: “Biomarkers for EGFR Therapy in NSCLC” (consensus planned to be published in Lancet).
Santa Monica, CA, US IASLC: 11th IASLC Conference on Targeted Therapy in Lung Cancer.
Invited Speaker:” Predictive and Prognostic Biomarkers for IGF-1R directed Therapy in NSCLC.”
Prague, Check Republic: 2. Prague Interdisciplinary Oncology Colloquium- Prague ONCO 2011 (Charles University, Prague):
Invited Key-Note Speaker: "Targeted Therapy in NSCLC-prognostic and predictive tools for bedside use?"
Emory University, Atlanta, US: Grand Round.
Invited lecture: "Development of Biomarkers for Personalized Lung Cancer therapy”
Japanese Lung Cancer Society 51. Annual Meeting, Hiroshima, JP
Invited Speaker: "Personalized Medicine in Lung Cancer".
2010 ASCO/IASLC/ASTRO Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL. Invited speaker.
4th Asia Pacific Lung Cancer Congress, Seoul, Korea. Invited speaker
ASCO/NCI/EORTC Cancer Conference, Hollywood, FL. Biomarkers for EGFR and IGFR directed therapies. Invited Speaker.
The 6th new York Lung Symposium. Molecular profiling in Lung Cancer: Existing and Emerging Molecular Cohorts (CME). Invited speaker
51 Annual Meeting Japan Lung Cancer Society (invited speaker). Future development of biomarkers and personalized medicine in lung cancer (received 2010 Merit Award) Invited speaker
Third Australian Lung Cancer Conference, Melbourne, Australia (invited speaker) 1. EGFR testing 2010; 2. Future research in biomarker development and clinical trials.
Beijing, China/ Personalized Medicine in NSCLC – EGFR mutation testing. Invited Speaker
Guangzhou, China. NSCLC Personalized medicine. Invited Speaker
Kuala Lumpur, Malaysia. NSCLC – personalized medicine. One World Hotel. Invited Speaker for oncologists, pathologists and pulmonologists. Invited speaker
Singapore: National University Cancer Center. Personalized Medicine in Lung Cancer: A paradigm Shift. Invited Speaker
Parlos Verdes, CA, US: 11th International Lung Cancer Congress: Personalized Medicine in NSCLC:
Single biomarker or Molecular Signatures? Invited Speaker
Lung Cancer Partnership, Chicago: Personalized Medicine in NSCLC: Biomarkers. Invited Speaker
Karolinska Insittute, Stockholm, Sweden. “ EGFR inhibition in NSCLC and how to select patients”. Invited Speaker
Tucson Symposium: IGF-1R as a prognostic and potential predictive biomarker in NSCLC Invited Speaker
27 IASLC Molecular Targeted Therapy Meeting, Santa Monica: “EGFRTKI & Chemotherapy”. “The Role of EGFR inhibition in NSCLC.” Invited Speaker.
University of Indiana: Grand Rounds. Invited speaker
MD Anderson Cancer Center Science Day: “EGFR inhibitions in NSCLC.” Invited Speaker
AACR-IASLC Joint Conference: Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy. Loews Coronado Bay Resort Coronado, California. “Gene Copy Number for EGFR and IGF-1R: Clinical Implications.” Invited Speaker.